JP2023508325A5 - - Google Patents
Info
- Publication number
- JP2023508325A5 JP2023508325A5 JP2022538213A JP2022538213A JP2023508325A5 JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5 JP 2022538213 A JP2022538213 A JP 2022538213A JP 2022538213 A JP2022538213 A JP 2022538213A JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- aforementioned
- product according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952114P | 2019-12-20 | 2019-12-20 | |
| US62/952,114 | 2019-12-20 | ||
| US202063009758P | 2020-04-14 | 2020-04-14 | |
| US63/009,758 | 2020-04-14 | ||
| PCT/US2020/065408 WO2021127043A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508325A JP2023508325A (ja) | 2023-03-02 |
| JP2023508325A5 true JP2023508325A5 (cg-RX-API-DMAC7.html) | 2023-12-25 |
Family
ID=76478082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538213A Pending JP2023508325A (ja) | 2019-12-20 | 2020-12-16 | 組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230053946A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069225A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023508325A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119657A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115023224A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020407572A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012266A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165382A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294068A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007627A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202142234A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127043A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| WO2021063967A1 (en) | 2019-10-01 | 2021-04-08 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| CA3160897A1 (en) | 2019-12-09 | 2021-06-17 | Sanofi | Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合 |
| IL302152B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| IL302153B1 (en) | 2020-10-19 | 2026-07-01 | Sanofi Sa | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES |
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
| CN119524139A (zh) * | 2023-08-28 | 2025-02-28 | 海创药业股份有限公司 | 一种雌激素蛋白靶向降解剂的联合用药物及其用途 |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| CN122421961A (zh) * | 2023-10-30 | 2026-07-17 | 密歇根大学董事会 | 双重功能免疫调节化合物、其制剂及用途 |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| CN119950496B (zh) * | 2024-12-24 | 2025-11-21 | 华东师范大学 | 靶向slc7a7的抑制剂在制备治疗肺癌骨转移癌药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39740A (fr) * | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| US20180002344A1 (en) * | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
-
2020
- 2020-12-16 EP EP20902430.6A patent/EP4069225A4/en not_active Withdrawn
- 2020-12-16 AU AU2020407572A patent/AU2020407572A1/en not_active Abandoned
- 2020-12-16 KR KR1020227024836A patent/KR20220119657A/ko not_active Ceased
- 2020-12-16 CN CN202080095155.1A patent/CN115023224A/zh active Pending
- 2020-12-16 JP JP2022538213A patent/JP2023508325A/ja active Pending
- 2020-12-16 IL IL294068A patent/IL294068A/en unknown
- 2020-12-16 CA CA3165382A patent/CA3165382A1/en active Pending
- 2020-12-16 US US17/757,485 patent/US20230053946A1/en not_active Abandoned
- 2020-12-16 BR BR112022012266A patent/BR112022012266A2/pt not_active IP Right Cessation
- 2020-12-16 MX MX2022007627A patent/MX2022007627A/es unknown
- 2020-12-16 WO PCT/US2020/065408 patent/WO2021127043A1/en not_active Ceased
- 2020-12-18 TW TW109145154A patent/TW202142234A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507797A5 (cg-RX-API-DMAC7.html) | ||
| Roche et al. | Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial | |
| JP5424923B2 (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
| JP2019529581A5 (cg-RX-API-DMAC7.html) | ||
| JP2018514511A5 (cg-RX-API-DMAC7.html) | ||
| JP2006512281A (ja) | 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用 | |
| RU2019114079A (ru) | Лечение er+ рака молочной железы лазофоксифеном | |
| JP2023507799A5 (cg-RX-API-DMAC7.html) | ||
| Randall et al. | Cytoreductive surgery for ovarian cancer | |
| Curry et al. | Second-look laparotomy for ovarian cancer | |
| Takahashi et al. | Clinicopathological features of early and late recurrence of endometrial carcinoma after surgical resection | |
| Howell et al. | Are aromatase inhibitors superior to antiestrogens? | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| Malik et al. | Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach? | |
| CN100408036C (zh) | 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途 | |
| KR20240073856A (ko) | 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료 | |
| Alektiar et al. | Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer | |
| Yousefnia | Breast cancer, subtypes, risk factors, and treatment | |
| CN120324434A (zh) | 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 | |
| Hu et al. | 5-aza-2’-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy | |
| Bae et al. | Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B–2B cervical cancer | |
| Vassilomanolakis et al. | A phase II study of flutamide in ovarian cancer | |
| Landreat et al. | Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases | |
| Di Legge et al. | Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer | |
| EP2821071A1 (en) | Compounds for breast cancer treatment |